Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
NCT03809481 · Aspen Global Incorporated · PHASE3 · terminated · last registry update 2022-12-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Prolonged delay as a result of impact of Covid19 pandemic” | – | Registry record, Aspen Global Incorporated |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPINC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-01Phase 3 first posted: Western University, Canada, Redesca (enoxaparin sodium for injection) + Fragmin (dalteparin) (NCT06153394)
- 2023-10-23Phase 3 first posted: Octapharma, Human plasma derived antithrombin + Placebo (NCT06096116)
- 2023-06-02Phase 3 first posted: Ain Shams University, Heparin (NCT05886998)
- 2023-06-01Results posted on the registry: University of Colorado, Denver, Insulin + Intralipid (NCT02653092)
- 2023-05-08Phase 3 first posted: University of Manitoba, Heparin (NCT05848713)
- 2023-03-06Results posted on the registry: Daiichi Sankyo, Edoxaban + Standard of Care (NCT02798471)
- 2023-02-01Phase 3 first posted: Beijing Tiantan Hospital, Acetazolamide-based medical therapy (NCT05707442)
- 2022-12-22Phase 3 first posted: Sanofi, Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) (NCT05662319)
- 2022-12-21Phase 3 first posted: Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
- 2022-11-23Phase 3 first posted: Galician Research Group on Digestive Tumors, Tinzaparin (NCT05625932)
- 2022-07-15Results posted on the registry: Janssen Research & Development, LLC, JNJ-70033093 25 mg + JNJ-70033093 50 mg (NCT03891524)
- 2022-04-01Phase 3 first posted: University Health Network, Toronto, Ketamine (NCT05306899)
- 2022-02-22Phase 3 first posted: Mario Negri Institute for Pharmacological Research, Recommended treatment schedule + Usual care (NCT05249790)
- 2022-02-07Phase 3 first posted: Medical University of Vienna, Argatroban + Unfractionated heparin (NCT05226442)
- 2022-01-24Phase 3 first posted: Murdoch Childrens Research Institute, unfractionated heparin + 0.9%sodium chloride (NCT05204550)
- 2021-12-28Phase 3 first posted: Anthos Therapeutics, Inc., Abelacimab + Dalteparin (NCT05171075)
- 2021-12-28Phase 3 first posted: Anthos Therapeutics, Inc., Abelacimab + Apixaban (NCT05171049)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision